The report "Autologous Stem Cell Non-stem Cell Therapies Market by Type (CAR-T, Tumor Infiltrating Lymphocyte), Indication (Cancer, Musculoskeletal, Dermatology), Source (T-Cells, Mesenchymal Stem Cell), End User (Hospital) - Global Forecast to 2029", is projected to reach USD 22.2 billion by 2029 from USD 5.5 billion in 2024, at a CAGR of 32.3% during the forecast period. One of the key factors driving the market growth is the growing regulatory approvals for autologous non-stem cell therapies such as autologous CAR T-cell therapies and Tumor Infiltrating Lymphocyte (TIL) therapies. Increasing RD investments for the development of novel autologous cell therapies is another factor contributing to the growth of the market.
Autologous non-stem cell therapies accounted for the largest share of the type segment in 2023.
Autologous non-stem cell therapies are an important sub-segment in the autologous stem cell non-stem cell therapies market for type segment. This sub-segment accounted for the largest market share of the autologous stem cell non-stem cell therapies market. This large share of the autologous non-stem cell therapies sub-segment can be attributed to the rising approvals for CAR T cell therapies and the growing incidence of global cancer cases which is impacting millions of individuals, increasing the demand for the development of effective treatment options such as autologous CAR T cell therapies.
Cancer Indications accounted for the largest share of the indication segment in the autologous stem cell non-stem cell therapies market in 2023.
By indication, the autologous stem cell non-stem cell therapies market is divided into cancer, musculoskeletal, dermatology, and other indications such as autoimmune disorders, spinal cord injuries, and ocular defects, among others.
Cancer Indications accounted for the largest share of the autologous stem cell non-stem cell therapies market in 2023. The large share of this market is attributed to factors such as the increasing number of global cancer cases resulting in a rising demand for cancer therapeutics, and ongoing RD to develop more effective therapies for the treatment of various forms of cancer including solid tumors.
The hospitals and clinics subsegment accounted for the largest share of the end user segment in the autologous stem cell non-stem cell therapies market in 2023.
In 2023, hospitals and clinics accounted for the largest share of the end-user segment of the autologous stem cell non-stem cell therapies market. The largest share is due to the increasing number of regulatory approvals for autologous non-stem cell therapies for the treatment of various forms of cancer and other chronic diseases. The increasing global burden of cancer has propelled the development of novel therapies to combat these diseases. Hospitals provide the infrastructure for apheresis, the process of collecting cells from the patient. This procedure is crucial for developing autologous cell therapies, as it ensures the quality and viability of the cells to be used. Biopharmaceutical firms continuously partner with hospitals to streamline the process, ensuring that patients receive treatments promptly and efficiently.
North America to register the highest CAGR in the autologous stem cell non-stem cell therapies market.
The North American region is expected to register the highest CAGR of the autologous stem cell non-stem cell therapies market. The rising investments for autologous stem cell and non-stem cell-based research, expansion of the healthcare sector, growing cancer prevalence, and the increasing approval and adoption of autologous stem cell and non-stem cell-based therapies for treating cancer and other chronic diseases are expected to aid market growth in North America.
Some leading players operating in the autologous stem cell non-stem cell therapies market are Gilead Sciences, Inc. (US), Bristol-Myers Squibb Company (US), Johnson Johnson (US), Vericel Corporation (US), Novartis AG (Switzerland), JW (Cayman) Therapeutics Co. Ltd (China), Iovance Biotherapeutics, Inc. (US), APAC Biotech (India), Regrow Biosciences Pvt Ltd. (India), healiva SA (Switzerland), Green Cross Holdings Co., Ltd. (GC Cell) (Republic of Korea), Sanpower Group Co., Ltd. (Dendreon Pharmaceuticals Llc. (China), Tegoscience (South Korea), ImmunoACT (India), CARsgen Therapeutics Holdings Limited (China), IASO Biotherapeutics (China), Pharmicell Co., Ltd (South Korea), Anterogen.Co., Ltd. (South Korea)
Source: https://www.marketsandmarkets.com/Market-Reports/autologous-cell-therapy-market-837.html
